LCM
KYNB

Laurion Capital Management’s Kyntra Bio KYNB Stock Holding History

Laurion Capital Management’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-807
Closed -$817K – 936
2020
Q2 		$817K Buy
+807
New +$749K 0.01% 508

Other funds holding KYNB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Laurion Capital Management's KYNB Position: Q3 2020 in Review

Laurion Capital Management sold out of Kyntra Bio (KYNB) in Q3 2020, closing a stake of 807 shares — an estimated $817K sold.

Laurion Capital Management first reported a position in KYNB in Q2 2020 and held it in 1 quarter. The position peaked at $817K in Q2 2020. 208 funds tracked by Wall St. Rank hold KYNB as of Q3 2020.

  • Laurion Capital Management reported no remaining Kyntra Bio position as of Q3 2020 after selling out during the quarter.
  • Laurion Capital Management sold 807 Kyntra Bio shares in Q3 2020, an estimated $817K.
  • Laurion Capital Management first reported a position in Kyntra Bio in Q2 2020 and held it in 1 quarter.
  • Laurion Capital Management's Kyntra Bio position peaked at $817K in Q2 2020.
  • 208 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2020.

Based on Laurion Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.